Literature DB >> 17021749

p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.

Yuan-Tzu Lan1, Shih-Ching Chang, Anna Fen-Yau Li, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Jen-Kou Lin.   

Abstract

BACKGROUND AND AIMS: p53 protein plays a crucial role in the pathogenesis of a large number of malignancies. In this study, our goal was to elucidate the prognostic role of p53 overexpression and its relationship to clinicopathological variables in colorectal cancer.
MATERIALS AND METHODS: Between 1999 and 2004, surgical specimens of 258 patients who received surgical treatment for colorectal cancer at the Veterans General Hospital, Taipei were collected. p53 expression in tumor tissue was evaluated by immunohistochemical analysis using the human p53-specific mouse monoclonal antibody, PAb 1801.
RESULTS: Of the 258 patients, 97 (37.6%) had overexpression of p53 in tumor tissues. The accumulation of p53 protein in tumor tissues did not correlate with age, gender, preoperative serum carcinoembryonic antigen (CEA) level, mucin content, nodal status, and tumor stage. A statistically significant correlation was found between p53 overexpression and location of the tumor in the rectum (p=0.038). Well to moderately differentiated tumors had significantly higher frequency of p53 overexpression than poorly differentiated tumors (40.0 vs 20.0%, p=0.050). Each patient was followed up for a minimum of 2 years (median 35 months). In univariate analysis, 3-year cancer-specific survival rate was significantly higher in patients with tumor p53 overexpression (88.2%) than in patients without overexpression (log rank test, p=0.037). However, in multivariate analysis, the tumour node metastasis stage remained the most significant independent prognostic factor.
CONCLUSION: The accumulation of p53 protein might have a favorable prognostic value in colorectal cancer, but it is not an independent prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021749     DOI: 10.1007/s00384-006-0194-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  39 in total

1.  TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.

Authors:  L H Sobin; I D Fleming
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

2.  Colorectal cancer prognosis: is it all mutation, mutation, mutation?

Authors:  A B Hassan; C Paraskeva
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

Authors:  D J Ahnen; P Feigl; G Quan; C Fenoglio-Preiser; L C Lovato; P A Bunn; G Stemmerman; J D Wells; J S Macdonald; F L Meyskens
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

4.  Prognostic markers for colorectal cancer: expression of P53 and BCL2.

Authors:  H Pereira; S Silva; R Julião; P Garcia; F Perpétua
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

5.  Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.

Authors:  Shih-Ching Chang; Jen-Kou Lin; Tzu-Chen Lin; Wen-Yih Liang
Journal:  Int J Oncol       Date:  2005-01       Impact factor: 5.650

6.  Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

Authors:  Megan M Garrity; Lawrence J Burgart; Michelle R Mahoney; Harold E Windschitl; Muhammad Salim; Martin Wiesenfeld; James E Krook; John C Michalak; Richard M Goldberg; Michael J O'Connell; Alfred F Furth; Daniel J Sargent; Linda M Murphy; Eunice Hill; Darren L Riehle; Cecelia H Meyers; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  p53 point mutation and survival in colorectal cancer patients.

Authors:  H S Goh; J Yao; D R Smith
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  p53 alterations are associated with improved prognosis in distal colonic carcinomas.

Authors:  R Soong; F Grieu; P Robbins; B Dix; D Chen; R Parsons; A House; B Iacopetta
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

9.  Expression of high p53 levels in colorectal cancer: a favourable prognostic factor.

Authors:  E Adrover; M L Maestro; M T Sanz-Casla; V del Barco; J Cerdán; C Fernández; J L Balibrea
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.

Authors:  A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  10 in total

1.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

2.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

3.  The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients.

Authors:  Mohammed Aladhraei; Eman Al-Salami; Naravat Poungvarin; Prasit Suwannalert
Journal:  J Gastrointest Oncol       Date:  2019-06

4.  High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.

Authors:  Lei Zheng; Ganfeng Xie; Guangjie Duan; Xiaochu Yan; Qianwei Li
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

Review 5.  The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.

Authors:  Eliane C M Zeestraten; Anne Benard; Marlies S Reimers; Philip C Schouten; Gerrit J Liefers; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  Biomark Cancer       Date:  2013-07-04

6.  The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery.

Authors:  Da-Zhong Cao; Xi-Long Ou; Ting Yu
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

7.  The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status.

Authors:  Martin Kruschewski; Kathrin Mueller; Sybille Lipka; Jan Budczies; Aurelia Noske; Heinz Johannes Buhr; Sefer Elezkurtaj
Journal:  Cancers (Basel)       Date:  2011-03-11       Impact factor: 6.639

8.  The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67.

Authors:  Il Yong Shin; Na Young Sung; Youn Soo Lee; Taek Soo Kwon; Yoon Si; Yoon Suk Lee; Seong Taek Oh; In Kyu Lee
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

9.  Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Dariusz Bielicki; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Cell Oncol (Dordr)       Date:  2013-11-26       Impact factor: 6.730

10.  Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Authors:  Hiroki Osumi; Eiji Shinozaki; Mitsukuni Suenaga; Yosuke Kumekawa; Mariko Ogura; Masato Ozaka; Satoshi Matsusaka; Keisho Chin; Noriko Yamamoto; Nobuyuki Mizunuma
Journal:  BMC Cancer       Date:  2015-10-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.